AIDS Funding Shifts to the Laboratory

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 4
Volume 4
Issue 4

WASHINGTON--William Paul, MD, director of the NIH Office of AIDS Research, has announced that AIDS funding will begin to shift away from clinical research toward investigator-initiated laboratory research. He said that continuation of past policies will result in only "slow, fitful progress."

WASHINGTON--William Paul, MD, director of the NIH Office of AIDSResearch, has announced that AIDS funding will begin to shiftaway from clinical research toward investigator-initiated laboratoryresearch. He said that continuation of past policies will resultin only "slow, fitful progress."

Dr. Paul appointed a new task force, chaired by Arnold Levine,a Princeton University molecular biologist, to determine researchpriorities.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content